Voy­ager goes big, se­cur­ing mul­ti-bil­lion dol­lar gene ther­a­py de­vel­op­ment deal with Neu­ro­crine

The neu­ro­log­i­cal dis­ease out­fit helmed by Bio­gen’s for­mer R&D chief an­nounced a big gene ther­a­py deal Mon­day, start­ing #JPM23 with its largest deal to date.

Voy­ager Ther­a­peu­tics is once again go­ing af­ter gene ther­a­pies with Neu­ro­crine Bio­sciences. The two teamed up on a large pact in 2019, but the Parkin­son’s por­tion of the tie-up fiz­zled out in Feb­ru­ary 2021. The work on Friedre­ich’s atax­ia from that deal re­mains on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER